Access to anti-retroviral drugs, female in Australia

Australia: Access to anti-retroviral drugs, female was 87.0% in 2023. ▲ Rising

Latest (2023)
87.0%
Change on year
up 7.4%
World rank
45th
of 141 countries
All-time high
87.0%
in 2023
All-time low
49.0%
in 2003
Years of data
24
2000–2023

Access to anti-retroviral drugs, female in Australia, 2000–2023

0204060802000201120232000: 53 %2001: 54 %2002: 50 %2003: 49 %2004: 49 %2005: 51 %2006: 53 %2007: 53 %2008: 52 %2009: 53 %2010: 58 %2011: 61 %2012: 63 %2013: 61 %2014: 63 %2015: 68 %2016: 69 %2017: 72 %2018: 73 %2019: 76 %2020: 79 %2021: 79 %2022: 81 %2023: 87 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, female in Australia stood at 87.0%. That is the highest value across all 24 years on record.

The figure is up 7.4% on the previous year and up 42.6% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Australia peaked at 87.0% in 2023 and was at its lowest, 49.0%, in 2003.

Australia ranks 45th of 141 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, female in Australia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Australia, 2000 to 2023.
Year % Change
2000 53.0%
2001 54.0% +1.9%
2002 50.0% -7.4%
2003 49.0% -2.0%
2004 49.0% +0.0%
2005 51.0% +4.1%
2006 53.0% +3.9%
2007 53.0% +0.0%
2008 52.0% -1.9%
2009 53.0% +1.9%
2010 58.0% +9.4%
2011 61.0% +5.2%
2012 63.0% +3.3%
2013 61.0% -3.2%
2014 63.0% +3.3%
2015 68.0% +7.9%
2016 69.0% +1.5%
2017 72.0% +4.3%
2018 73.0% +1.4%
2019 76.0% +4.1%
2020 79.0% +3.9%
2021 79.0% +0.0%
2022 81.0% +2.5%
2023 87.0% +7.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 51.7% 49.0% 54.0% 10
2010s 66.4% 58.0% 76.0% 10
2020s 81.5% 79.0% 87.0% 4

Countries ranked near Australia

  1. 44 Uganda 88.0% compare
  2. 45 Luxembourg 87.0% compare
  3. 47 Iceland 86.0% compare
  4. 47 Peru 86.0% compare

See the full ranking of 160 places →

More gender data for Australia

All data for Australia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Australia?
Access to anti-retroviral drugs, female in Australia was 87.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Australia?
The highest recorded value was 87.0% in 2023.
What is the lowest access to anti-retroviral drugs, female recorded in Australia?
The lowest recorded value was 49.0% in 2003.
How does Australia rank for access to anti-retroviral drugs, female?
Australia ranks 45th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, female rising or falling in Australia?
Over the last ten years it is up 42.6%. The long-run trend across the full record is rising.
Where does this Australia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Australia. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/australia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/australia/">Access to anti-retroviral drugs, female in Australia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.